Simplex Trading’s Krystal Biotech KRYS Stock Holding History

Simplex Trading’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50	Closed	-$14.9K	–	9839
2026 Q1	$12.9K	Sell	50 -243	-83%	-$64.7K	﹤0.01%	7124
2025 Q4	$72.2K	Buy	+293	New	+$61.7K	﹤0.01%	5310
2023 Q4	–	Sell	-27	Closed	-$2.99K	–	9351
2023 Q3	$3K	Sell	27 -5,162	-99%	-$630K	﹤0.01%	7914
2023 Q2	$609K	Buy	+5,189	New	+$530K	﹤0.01%	3103
2022 Q2	–	Sell	-26	Closed	-$1.62K	–	10545
2022 Q1	$1K	Buy	+26	New	+$1.62K	﹤0.01%	10094
2021 Q4	–	Sell	-5,025	Closed	-$292K	–	10949
2021 Q3	$360K	Sell	5,025 -500	-9%	-$29.6K	﹤0.01%	4616
2021 Q2	$375K	Buy	+5,525	New	+$386K	﹤0.01%	4609
2020 Q4	–	Sell	-1,231	Closed	-$61.5K	–	8724
2020 Q3	$52K	Buy	1,231 +1,169	+1,885%	+$50.8K	﹤0.01%	5568
2020 Q2	$2K	Buy	+62	New	+$2.98K	﹤0.01%	7254

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Simplex Trading's KRYS Position: Q2 2026 in Review

Simplex Trading sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 50 shares — an estimated $14.9K sold.

Simplex Trading first reported a position in KRYS in Q2 2020 and held it in 9 quarters. The position peaked at $609K in Q2 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Simplex Trading reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Simplex Trading sold 50 Krystal Biotech shares in Q2 2026, an estimated $14.9K.
Simplex Trading first reported a position in Krystal Biotech in Q2 2020 and held it in 9 quarters.
Simplex Trading's Krystal Biotech position peaked at $609K in Q2 2023.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.